|

Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer

RECRUITINGSponsored by Fondazione Policlinico Universitario Campus Bio-Medico
Actively Recruiting
SponsorFondazione Policlinico Universitario Campus Bio-Medico
Started2023-05-17
Est. completion2029-05-17
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07021911

Summary

The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients suffering from stage IV breast cancer
* Ongoing systemic treatment including: molecular targeted therapy, conjugated antibodies, monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy (immunocheckpoint inhibitors)
* Candidates for radiation treatment (both palliative and curative).

Exclusion Criteria:

* Previous radiation treatment on the same site
* Absolute contraindications to radiotherapy
* Systemic treatment administered as part of a clinical trial

Conditions3

Breast CancerCancerRadiotherapy; Complications

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.